Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.

The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study. BMJ Open (2012) 1.24

[When are drug-eluting stents effective? A critical analysis of the presently available data]. Z Kardiol (2004) 1.06

Drug-eluting stent: a review and update. Vasc Health Risk Manag (2005) 0.88

Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting. Heart (2005) 0.86

Late outcomes following percutaneous coronary interventions: results from a large, observational registry. Can J Cardiol (2010) 0.82

Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound. Cardiovasc Ultrasound (2004) 0.80

Everolimus-eluting stents in interventional cardiology. Vasc Health Risk Manag (2012) 0.80

The cell cycle: a critical therapeutic target to prevent vascular proliferative disease. Can J Cardiol (2006) 0.79

Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice. Can J Cardiol (2008) 0.79

Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry. Heart (2006) 0.79

Contemporary Use of Drug-eluting Stents. Curr Treat Options Cardiovasc Med (2005) 0.78

Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) (2014) 0.77

Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. Vasc Health Risk Manag (2007) 0.76

Drug-eluting coronary stents - focus on improved patient outcomes. Patient Relat Outcome Meas (2011) 0.76

The stenting strategy of drug-eluting stents for coronary artery disease in patients on dialysis. SAGE Open Med (2014) 0.76

Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovasc Disord (2005) 0.76

Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J (2011) 0.76

Comparison of Long-Term Clinical Outcomes after Drug-Eluting Stent Implantation in Patients with Coronary Artery Disease with and without Prior Cerebral Infarction. Ann Vasc Dis (2015) 0.75

Influence of increased epicardial adipose tissue volume on 1-year in-stent restenosis in patients who received coronary stent implantation. J Geriatr Cardiol (2016) 0.75

Safety and efficacy of a non-polymeric paclitaxel-eluting microporous stent in real-world percutaneous coronary intervention. Exp Ther Med (2013) 0.75

Bringing reality to drug-eluting stents. Circulation (2004) 0.75

Nickel-free stainless steel avoids neointima formation following coronary stent implantation. Sci Technol Adv Mater (2012) 0.75

Attending to links in the safety chain for drug-eluting stents. Neth Heart J (2006) 0.75

Percutaneous coronary intervention in unprotected left main stem disease: the state of play. Heart (2005) 0.75

Choosing a revascularization strategy in patients with diabetes and stable coronary artery disease: a complex decision. Curr Cardiol Rev (2010) 0.75

Drug-eluting stents for all patients. Neth Heart J (2006) 0.75

The practicing physician's current perspective on therapeutic options in coronary artery disease. Neth Heart J (2005) 0.75

Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine (Baltimore) (2016) 0.75

Influence of valsartan-eluting stent on neointima formation. J Cardiovasc Dis Res (2010) 0.75

Sirolimus-Eluting Stents vs Uncoated Stents for the Treatment of Proximal Left Anterior Descending Coronary Artery Stenosis. Int J Biomed Sci (2007) 0.75

Six-months patency of three long drug eluting stents documented by surveillance coronary multi-detector computed tomography (MDCT). Clin Res Cardiol (2006) 0.75

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61

Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol (2008) 7.56

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet (2010) 4.87

Reliable noninvasive coronary angiography with fast submillimeter multislice spiral computed tomography. Circulation (2002) 4.78

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation (2007) 4.71

High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (2013) 3.41

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 3.36

Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29

A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart J (2011) 3.14

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12

Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06

Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91

Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90

Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation (2013) 2.88

Stent thrombosis. J Am Coll Cardiol (2010) 2.86

Noncardiac findings in cardiac imaging with multidetector computed tomography. J Am Coll Cardiol (2006) 2.86

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85

Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol (2008) 2.81

Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. Ann Intern Med (2010) 2.80

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet (2011) 2.67

Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med (2011) 2.65

Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J (2010) 2.62

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet (2008) 2.57

Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol (2003) 2.56

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54

Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50

Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43

Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation (2010) 2.40

Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36

Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32

Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30

Intravenous contrast material administration at 16-detector row helical CT coronary angiography: test bolus versus bolus-tracking technique. Radiology (2004) 2.28

Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24

Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20

2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management. Heart (2013) 2.18

Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation (2011) 2.17

Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14

Do risk factors influence the diagnostic accuracy of noninvasive coronary angiography with multislice computed tomography? J Nucl Cardiol (2006) 2.14

Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv (2004) 2.12

Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

The obesity paradox in patients with peripheral arterial disease. Chest (2008) 2.09

Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation (2008) 2.07

Characterizing vulnerable plaque features with intravascular elastography. Circulation (2003) 2.07

The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med (2005) 2.05

Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv (2004) 2.04